Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jannick A.N. Dorresteijn"'
Autor:
Daniël Duijzer, Maria A. de Winter, Marc Carrier, Alexander T. Cohen, John-Bjarne Hansen, Karin A.H. Kaasjager, Ajay K. Kakkar, Saskia Middeldorp, Henrik T. Sørensen, Frank L.J. Visseren, Philip S. Wells, Jannick A.N. Dorresteijn, Mathilde Nijkeuter
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 7, Pp 102569- (2024)
Background: After 3 months of anticoagulation for venous thromboembolism (VTE), the decision needs to be made whether to stop anticoagulation or extend treatment indefinitely. The VTE-PREDICT calculator can be used to estimate individual risks of VTE
Externí odkaz:
https://doaj.org/article/762594d3a38a49cfa6a9cbbcee03a280
Autor:
Jannick A.N. Dorresteijn, MD, PhD, MSc, Steven H.J. Hageman, MD, PhD, MSc, Frank L.J. Visseren, MD, PhD, Deepak L. Bhatt, MD, MPH, MBA
Publikováno v:
JACC: Advances, Vol 3, Iss 9, Pp 101089- (2024)
Externí odkaz:
https://doaj.org/article/c7e68e008bb7474da86264e622ea27d7
Autor:
Lotte Kaasenbrood, Deepak L. Bhatt, Jannick A.N. Dorresteijn, Peter W.F. Wilson, Ralph B. D'Agostino, Joseph M. Massaro, Yolanda van der Graaf, Maarten J.M. Cramer, L. Jaap Kappelle, Gert J. de Borst, Ph. Gabriel Steg, Frank L. J. Visseren
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 16 (2018)
Background In patients with vascular disease, risk models may support decision making on novel risk reducing interventions, such as proprotein convertase subtilisin/kexin type 9 inhibitors or anti‐inflammatory agents. We developed and validated an
Externí odkaz:
https://doaj.org/article/fcf15e92d6714e9fb9df0b26b073df88
Autor:
Manon C. Stam‐Slob, Yolanda van der Graaf, Jacoba P. Greving, Jannick A.N. Dorresteijn, Frank L.J. Visseren
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 2 (2017)
BackgroundA validated prediction model estimates the absolute benefit of intensive versus standard lipid‐lowering therapy (LLT) with statins on next major cardiovascular events for individual patients with coronary artery disease. We aimed to asses
Externí odkaz:
https://doaj.org/article/fbb33fd68be64b34a70ece2de1298e1d
Autor:
Pascal M. Burger, Aruna D. Pradhan, Jannick A.N. Dorresteijn, Stefan Koudstaal, Martin Teraa, Gert J. de Borst, Manon G. van der Meer, Arend Mosterd, Paul M. Ridker, Frank L.J. Visseren
Publikováno v:
The American Journal of Cardiology. 197:13-23
Autor:
Pascal M. Burger, Stefan Koudstaal, Jannick A.N. Dorresteijn, Gianluigi Savarese, Manon G. van der Meer, Gert J. de Borst, Arend Mosterd, Frank L.J. Visseren
Publikováno v:
International Journal of Cardiology. 379:66-75
Autor:
Helena Bleken Østergaard, Stephanie H. Read, Naveed Sattar, Stefan Franzén, Nynke Halbesma, Jannick A.N. Dorresteijn, Jan Westerink, Frank L.J. Visseren, Sarah H. Wild, Björn Eliasson, Joep van der Leeuw
Publikováno v:
Østergaard, H B, Read, S H, Sattar, N, Franzén, S, Halbesma, N, Dorresteijn, J A N, Westerink, J, Visseren, F L J, Wild, S H, Eliasson, B & van der Leeuw, J 2022, ' Development and Validation of a Lifetime Risk Model for Kidney Failure and Treatment Benefit in Type 2 Diabetes : 10-Year and Lifetime Risk Prediction Models ', Clinical Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 1783-1791 . https://doi.org/10.2215/CJN.05020422
BACKGROUND AND OBJECTIVES: Individuals with type 2 diabetes are at a higher risk of developing kidney failure. The objective of this study was to develop and validate a decision support tool for estimating 10-year and lifetime risks of kidney failure